A Case of Rituximab Therapy in Diffuse Alveolar Hemorrhage of Systemic Lupus Erythematosus Refractory to Steroid Pulse Therapy.
10.4078/jrd.2014.21.4.201
- Author:
Sang Woo YIM
1
;
Chang Kyoo BYON
;
Jun Yong PARK
;
Sang Yeob LEE
;
Sung Won LEE
;
Won Tae CHUNG
Author Information
1. Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, Korea. wtchung@dau.ac.kr
- Publication Type:Case Report
- Keywords:
Rituximab;
Diffuse alveolar hemorrhage;
Systemic lupus erythematosus
- MeSH:
Adult;
Antigens, CD20;
B-Lymphocytes;
Female;
Hemorrhage*;
Humans;
Lupus Erythematosus, Systemic*;
Nephritis;
Thrombocytopenia;
Vasculitis;
Rituximab
- From:Journal of Rheumatic Diseases
2014;21(4):201-204
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Rituximab is a chimeric murine-human monoclonal antibody that is directed against the specific B-cell CD20 antigen, which has recently been successfully used in active or refractory systemic lupus erythematosus (SLE) manifestations, such as nephritis, thrombocytopenia, and vasculitis. We report a case of a 25-year-old woman diagnosed with diffuse alveolar hemorrhage of SLE refractory to steroid pulse therapy. The patient was treated successfully with rituximab as a part of the immunosuppressive regimen.
